Scinovex
article Open Access

Efficacy of Crotalus horridus as an adjunct therapy in canine babesiosis

International Journal of Advanced Biochemistry Research · 2026 · Vol. 10(7) · pp. 1015–1022
Vishal Singh BhatiRavindra JadhavB. N. AmboreRajendra GhadgePrashant PawarChandrakant MoteABHIJIT BARATE

Abstract

Canine babesiosis caused by Babesia gibsoni is a clinically significant hemoprotozoan disease characterized by hemolytic anemia, persistent thrombocytopenia, and frequent relapse after treatment. Conventional therapeutic regimens often improve clinical signs but may not ensure sustained parasitological clearance. The present scientific article evaluates the comparative therapeutic efficacy of Crotalus horridus 200C as an adjunct therapy to standard antimicrobial treatment in naturally occurring Babesia gibsoni infection. A total of 74 clinically suspected dogs were screened, of which 30 PCR-confirmed B. gibsoni positive dogs were randomly allocated into three treatment groups: Group A received doxycycline-enrofloxacin-metronidazole, Group B received the same regimen with adjunct Crotalus horridus 200C, and Group C received diminazene aceturate. Comparative assessment was based on clinical recovery, hematobiochemical restoration, peripheral smear examination, and PCR negativity on days 0, 7, and 21. Group B demonstrated the best therapeutic response with 100% clinical recovery, faster normalization of hemoglobin, packed cell volume, and platelet counts, 80% PCR clearance, and absence of relapse by day 21. The findings indicate that Crotalus horridus acts as an effective adjunct in accelerating hematological and clinical recovery in canine Babesia gibsoni infection.

Full Text

Tables and figures are in the full-text PDF.

Introduction

Canine babesiosis is an important tick-borne hemoprotozoan disease caused by intraerythrocytic parasites of the genus Babesia, among which Babesia gibsoni is especially important due to its chronicity and high relapse rate. The disease may occur in acute, chronic, or subclinical forms and is primarily associated with fever, lethargy, hemolytic anemia, thrombocytopenia, and hepatic dysfunction. Persistent thrombocytopenia is considered one of the most consistent hematological hallmarks of B. gibsoni infection (Kettner et al., 2003) [16] . Conventional therapies include diminazene aceturate, imidocarb dipropionate, clindamycin-based combinations, and doxycycline-enrofloxacin-metronidazole protocols. However, no single treatment protocol has proven completely effective in eliminating the parasite, and many dogs remain chronic carriers with recurrent parasitemia (Jefferies et al., 2003) [13] . Because thrombocytopenia and hemorrhagic tendencies are major prognostic concerns, adjunct therapies capable of accelerating platelet recovery may improve clinical outcomes. Crotalus horridus, a homeopathic preparation traditionally indicated in hemorrhagic diathesis, jaundice, black vomit, and vascular disorders, has shown encouraging responses in canine ehrlichiosis and dengue-associated thrombocytopenia (Tungnunga et al., 2016; Nayak et al., 2019) [20,28] . Therefore, the present study was undertaken to comparatively evaluate the efficacy of Crotalus horridus as an adjunct therapy in naturally occurring canine babesiosis.

Swollen lymph node and hemoglobinuria. In order to confirm the diagnosis of Babesia gibsoni infection, the infected dogs in this study underwent clinical examination and diagnostic procedures such as Giemsa's stain peripheral blood smear testing, and polymerase chain reaction. About 5 mL blood sample was collected from each dog using a sterile disposable syringe via either cephalic or lateral saphenous venipuncture. Of this, approximately 3 mL was transferred into a K₂EDTA (ethylenediaminetetraacetic acid) vial for hematological analysis, blood smear examination, and genomic DNA extraction for polymerase chain reaction (PCR) testing to detect B. gibsoni DNA. The remaining 2 mL of blood, collected without anticoagulant, was placed in a separate vial for serum separation and biochemical analysis. Hematological parameters includes Hb (g/dl), Total Erythrocyte Count (x10 6 / µL), Packed Cell Volume (%), Mean Corpuscular Volume (fl), Mean Corpuscular Hemoglobin Concentration (g/dL), Total Leucocyte Count (x10 3 / µL), Differential Leucocyte Count (%) and Platelets Count (Lacs/µL). Abacus Junior vet 5 part machine were used for analysing hematological parameter before treatment on day 0 and after treatment on day 7 and 21. Serum samples were obtained by centrifuging the collected blood at 2500 rpm for 3 minutes. The separated serum was carefully transferred into sterile microtubes and stored at -20°C until further biochemical analyses were performed. Biochemical parameters includes Total Bilirubin (mg/dl), Direct Bilirubin (mg/dl), Indirect Bilirubin (mg/dl), Total Protein (g/dl), Albumin (g/dl), Globulin (g/dl), Alanine Aminotransferase (U/L), Aspartate Transferase (U/L), Blood Urea Nitrogen (mg/dl), Creatinine (mg/dl) and Alkaline Phosphatase (U/L). Biochemical evaluations were conducted using alta chem semi-automated clinical chemistry analyser (ADX-CHEM-220) before treatment on day 0 and after treatment on day 7 and 21. The molecular confirmation of the Babesia gibsoni parasites was carried out by PCR. DNA was extracted from the blood sample by applying the Phenol Chloroform method. Extracted DNA sample is used as template to amplify the fragment of Babesia gibsoni for 18S rRNA using the primers described by Inokuma et al. (2004) [10] . Specification of the primers are given below in the table no. 3.1 Extracted DNA was analyzed by agarose gel (1.5%) electrophoresis and visualization of band were done under UV transilluminator. 30 Babesia gibsoni positive cases were equally distributed into 3 equal groups (n=10). Group A was treated with Inj. Doxycycline @10 mg/kg IV SID for 21 days, Inj. Metronidazole @15mg/kg IV on first day followed by 8 mg/kg IV SID for next 20 days and Inj. Enrofloxacin @5 mg/kg IM SID for 21 days, Group B was treated with Inj. Doxycycline @10 mg/kg IV SID for 21 days, Inj.

Metronidazole @15mg/kg IV on first day followed by 8 mg/kg IV SID for next 20 days, Inj. Enrofloxacin @5 mg/kg IM SID for 21 days and Liq. Crotalus horridus 200C 5 ml Sub-lingual BID for 21 days and Group C was treated by Inj. Diminazene aceturate @3.5 mg/kg deep IM. [27] , Furlanello et al. (

, Bourdoiseau (2006) [5] and Irwin (2009) [11] . Elevated heart rate and respiratory rate in Babesia gibsoni infected dogs may be attributed to fever, hypoxia secondary to anemia and increased metabolic demand. Similar elevations in heart rate have been documented in dogs affected with babesiosis by Adebayo et al. (2016) [1] and Chaudhuri et al. (2017) [7] .

Hematological parameter

A progressive improvement in hemoglobin (Hb), Packed Cell Volume (PCV) and Total Erythrocyte Count (TEC) was recorded from day 0 to day 21 in all the groups, with the highest increase recorded in group B followed by group A, whereas group C showed comparatively lowered improvement. Group B showed significant (p < 0.05) increase in Hb, PCV between day 0 and day 21 while significant increase in TEC was observed between day 0 and day 7. Group A also showed significant increase in TEC between day 0 and day 21. The decrease in Hb, PCV and TEC values in the B. gibsoni infected dogs also confirms the anemia due to multifactorial etiology such as direct mechanical damage of RBC membrane by the parasites, splenic removal of the parasitised RBCs and immune mediated destruction of RBC were in close confirmation with the findings Salem and Farag (2014) [22] , Jain et al. (2017) [12] , Yogeshpriya et al. (2018) [29] , Mittal, et al. (2019) [19] , Anju et al. (2021) [2] , Liu et al. (2022) [18] , Reddy et al. (2024) [21] , Kaliuzhnyi et al. (2025) [14] . Increase in the Hb, PCV and TEC values in Babesia gibsoni infected dogs after the treatment due reduced erythrocyte destruction, Stabilization of circulating RBC's, reduction in parasitaemia similar observation were observed by Birkenheuer (2004) [4] , Selvaraj et al. (2010) [23] , Lin and Huang (2010) [17] , Lin et al. (2012), Shrivastva et al. (2014) [25] , Karasová et al. (2022) [15] and Bhasme et al. (2024) [3] . The Mean Corpuscular Volume (MCV) showed slight declining trend in group A, while group B and C exhibited gradual increase by day 21. The Mean Corpuscular Hemoglobin Concentration (MCHC) remained stable throughout the study period with minor fluctuation among the groups. These MCV and MCHC values showed minor variations but remained within a similar range, with no marked increase or decrease. The minimal alteration in the erythrocyte indices with normocytic normochromic anemia, which is typical of acute hemolytic conditions like Babesia gibsoni infection was observed in this study were in close conformation with the findings of Salem and Farag (2014) [22] , Anju et al. (2021) [2] . A decreasing trend is Total Leucocyte Count (TLC) was observed in group A, whereas group B and group C showed mild fluctuation with no marked alteration. After treatment the normalization of TLC count suggested reduction in inflammatory response is in close confirmation with the findings of Lin and Huang (2010) [17] , Solano-Gallego and Baneth (2011) [26] , Baneth et al. (2015) [31] and Karasová et al. (2022) [15] . Platelets counts increased significantly (p < 0.05) in group B between day 0 to day 7 and day 21. At day 21 platelets counts of group C had showed significant lowered count as compared to group A and group B. Marked thrombocytopenia were observed in this study in case of B. gibsoni infected dogs may result from immunemediated destruction, splenic sequestration due to splenomegaly or increased consumption similar findings were observed by Furlanello et al. (2005) [8] , Salem and Farag (2014) [22] , Jain et al. (2017) [12] , Yogeshpriya et al. (2018) [29] , Anju et al. (2021) [2] , Liu et al. (2022) [18] , Reddy et al. (2024) [21] , Kaliuzhnyi et al. (2025) [14] . Increase in the thrombocyte counts suggests improvement in bone marrow function, decrease spleen sequestration and reduction in immune mediated platelets destruction similar observation was reported Chaudhuri and Varshney (2007) [6] , Selvaraj et al. (2010) [23] , Nayak et al. (2019) [20] and Game et al. (2024) [9] . The significantly faster platelet recovery observed in Group B may be attributed to a combined effect of reduced parasitaemia, decreased immune-mediated platelet destruction, and early stabilization of vascular integrity. In Babesia gibsoni infection, thrombocytopenia is multifactorial and commonly results from splenic sequestration, peripheral consumption, endothelial injury, and immune-mediated destruction of circulating platelets. The adjunct use of Crotalus horridus 200C possibly accelerated reversal of these mechanisms, thereby promoting earlier restoration of platelet counts compared with conventional antimicrobial therapy alone. The Differential Leucocyte Count (DLC) recorded in different group at day 0, day 7 and day 21 is presented in the table no. percentage remained comparatively stable in group A throughout the study period, whereas Group B showed a gradual increase between day 0 to day 21 (70.0 ± 3.40 to 80.0 ± 1.89). Group C showed mild fluctuation during the experimental period. Lymphocyte percentage showed minor variation among all the groups. In group B, the values decreased from 27.0 ± 2.82 to 19.10 ± 1.82 at day 21, whereas Group A and C showed only slight fluctuations. Monocyte percentage remained low in all groups, with group B showing a decline to 0% by day 21. Eosinophil values exhibited mild variation, with a decreasing trend in group B and slight fluctuation in Group A and C. Basophils were absent in all the groups throughout the study period. Many researchers have also reported neutropenia and relative lymphocytosis due to chronic infections such as Salem and Farag (2014) [22] , Yogeshpriya et al. (2018) [29] , Anju et al. (2021) [2] .

Biochemical parameters

The serum biochemical parameters of different group at day 0, 7 and 21 are presented in the table no. Total protein, albumin and globulin values showed only minor fluctuation during the study periods in all groups. A comparatively increasing trend in total protein and albumin was observed in group B by day 21. Total bilirubin, direct bilirubin and indirect bilirubin showed decreasing trend in group B from day 0 to day 21. Significant decrease (p < 0.05) was observed in the direct bilirubin values in group B from day 0 to day 7 and day 21. Significant lowering (p < 0.05) of total bilirubin and direct bilirubin was observed in group C as compared to group A on day 7 while group B remain intermediate. In the present study, increase in total and direct (conjugated) bilirubin was observed in Babesia gibsoni-infected dogs, consistent with hemolysis and hepatic involvement. However, indirect (unconjugated) bilirubin did not show a significant change. This pattern elevated direct but stable indirect bilirubin has been documented in the study of Nagarjuna et al. (2024) [33] . Such findings suggest that although hemolysis produces large amounts of unconjugated bilirubin, the liver's conjugation mechanisms may still function sufficiently in the early stages of infection, with impaired excretion leading to accumulation mainly of the conjugated fraction. After treatment decrease in total and direct bilirubin values suggests reduction in hepatic inflammation and normalization of hepatic function similar observation were also reported by Baneth et al. (2015) [31] , Gonde et al. (2015) and Lakshmi et al. (2024) [32] . Hepatic enzymes activities revealed mild variation during the study period. ALT and AST values tended to decrease in group B by day 21, suggesting improvement in hepatic status. In this study the increase in the ALT and AST values in dogs infected with Babesia gibsoni infection suggest hepatocellular damage secondary to hypoxia and systemic inflammation similar findings were observed by Furlanello et al. (2005) [8] , Zygner et al. (2007) [30] , Mittal, et al. (2019) [19] , Liu et al. (2022) [18] , Reddy et al. (2024) [21] , Kaliuzhnyi et al. (2025) [14] . Similarly, ALP values showed marked reduction in group B on day 7 followed by partial recovery by day 21 which remained significantly different (p < 0.05) from day 0. Also, ALP value in group B was significant (p < 0.005) lowered as compared to group A on day 7. Serum ALP values remained within normal limits with only mild fluctuations among groups. No significant elevation was observed, suggesting minimal hepatobiliary involvement. Similar unchanged ALP activity in canine babesiosis has been reported by Shah et al. (2011) [24] and Zygner et al. (2007) [30] . Thus, ALP may not serve as a sensitive marker of hepatic damage in uncomplicated B. gibsoni infection. Renal function indicators namely BUN and Creatinine, remained within the normal physiological limits with minor fluctuation throughout the study period. Also, the creatinine value of group B was significant (p < 0.05) lower as compared to group A on day 7, whereas group C remained intermediate. In this study the mean creatinine and BUN values in dogs infected with Babesia gibsoni infection were mildly increased due to dehydration or remained in the normal ranges. This observation is in close confirmation with the findings of Anju et al. (2021) [2] .

Evaluation of blood smear examination and polymerase chain reaction

Peripheral blood smear examination showed a progressive decline in Babesia gibsoni parasitaemia in all treatment groups. On day 7, smear-based efficacy was 70% in Group A and 80% each in Groups B and C. By day 21, parasitological clearance reached 90% in all groups, with only one dog remaining smear positive in each group. Clinically, Group B showed complete recovery in all dogs, whereas Group C exhibited relapse in 30% of cases despite similar smear clearance. PCR evaluation revealed lower clearance rates compared to smear examination, reflecting its greater sensitivity in detecting residual infection. On day 7, PCR-based efficacy was 50% in Group A and 60% in Groups B and C. By day 21, Groups A and B achieved 80% molecular clearance, whereas Group C remained at 60%. These findings indicate superior sustained clinical and molecular efficacy of the combination therapy protocols, particularly in Group B, compared with diminazene aceturate monotherapy. Smear negativity alone may not indicate complete parasitological cure, and improved PCR clearance with absence of relapse in Group B suggests better control of chronic carrier status.

Comparative evaluation of therapeutic regimens

A comparison of all three treatment protocols revealed clear differences in outcomes. Group B had the best response, marked by quick clinical improvement, full recovery of all dogs, early normalization of blood parameters, and satisfactory clearance of parasitaemia. Group A also proved effective but required more time to achieve similar results. In contrast, Group C showed lower sustained efficacy, incomplete parasite removal, and higher relapse rates. Regarding blood recovery, Groups A and B displayed a progressive correction of anemia and thrombocytopenia, while Group C improvement was slower. Biochemical recovery was also more consistent in the combination therapy groups. These findings suggest that combination treatments offer broader and more effective with synergistic effect to control the infections and their systemic effects.

Conclusion

The present study concludes that adjunct administration of Crotalus horridus 200C with doxycycline-enrofloxacinmetronidazole therapy significantly enhanced therapeutic outcomes in dogs naturally infected with Babesia gibsoni. The adjunct protocol resulted in faster clinical improvement, superior correction of anemia and thrombocytopenia, improved biochemical recovery, higher molecular clearance, and complete prevention of relapse during the observation period compared with conventional therapy alone and diminazene aceturate monotherapy. The pronounced recovery of platelet counts highlights the potential supportive role of Crotalus horridus in managing hemorrhagic complications and persistent thrombocytopenia associated with canine babesiosis. Therefore, Crotalus horridus 200C may be considered a promising adjunct therapeutic option in the clinical management of canine babesiosis, particularly in cases showing severe hematological compromise. Further studies involving larger sample sizes and longer follow-up periods are recommended to validate its long-term role in parasitological clearance and prevention of carrier states.

References

  1. Adebayo OO, Ajadi RA, Omobowale TO, Omotainse SO, Dipeolu MA, Nottidge HO, et al. Reliability of clinical monitoring for the diagnosis of babesiosis in dogs in Nigeria. Veterinary Medicine: Research and Reports. 2016;7(1):85-90.
  2. Anju S, Vijaykumar K, Sulficar S, Shyma VH, Deepa PM. Haemato-biochemical changes associated with Babesia gibsoni infection in dogs. Journal of Veterinary and Animal Sciences. 2022;53(1):22-26.
  3. 3. Bhasme SD, Pajai KS, Dighe DG, Waghmare SP, Patil MD, Gutte PR. Diagnosis and therapeutic management of Babesia gibsoni infection in dogs using antimalarial drug therapy. The Pharma Innovation Journal. 2024;13(9):86-87.
  4. Birkenheuer AJ, Neel J, Ruslander D, Levy MG, Breitschwerdt EB. Detection and molecular characterization of a novel large Babesia species in a dog. Veterinary Parasitology. 2004;124(3-4):151-160.
  5. 5. Bourdoiseau G. Canine babesiosis in France. Veterinary Parasitology. 2006;138(1-2):118-125.
  6. Chaudhuri S, Varshney JP. Clinical management of babesiosis in dogs with homeopathic Crotalus horridus 200C. Homeopathy. 2007;96(02):90-94.
  7. 7. Chaudhuri S, Varshney JP, Changkija B. Electrocardiographic Changes in Canine Babesiosis. Arch Palliat Care. 2017;2(2):1014.
  8. Furlanello T, Fiorio F, Caldin M, Lubas G, SolanoGallego L. Clinicopathological findings in naturally occurring cases of babesiosis caused by large form Babesia from dogs of north-eastern Italy. Veterinary Parasitology. 2005;134(1-2):77-85.
  9. 9. Game YR, Dhoot VM, Bhojne GR, Panchbhai CG. Therapeutic Evaluation of Carica papaya Leaf Extract International Journal of Advanced Biochemistry Research https://www.biochemjournal.com and Crotalus horridus as Supportive Treatment in Canine Ehrlichiosis. Indian Journal of Canine Practice. 2024;16(2):125-129.
  10. Inokuma H, Yoshizaki Y, Matsumoto K, Okuda M, Onishi T, Nakagome K, et al. Molecular survey of Babesia infection in dogs in Okinawa, Japan. Veterinary Parasitology. 2004;121(3-4):341-346.
  11. 11. Irwin PJ. Canine babesiosis: from molecular taxonomy to control. Parasites and Vectors. 2009;2(1):S4 1-9.
  12. 12. Jain KJ, Lakshmanan B, Syamala K, Praveena JE, Aravindakshan T. High prevalence of small Babesia species in canines of Kerala, South India. Veterinary World. 2017;10(11):1319-1323.
  13. 13. Jefferies R, Ryan UM, Muhlnickel CJ, Irwin PJ. Two species of canine Babesia in Australia: detection and characterization by PCR. Journal of Parasitology. 2003;89(2):409-412.
  14. 14. Kaliuzhnyi N. Changes in morphological and biochemical blood parameters in dogs with babesiosis. Scientific Messenger of LNU of Veterinary Medicine and Biotechnologies Series: Veterinary Sciences. 2025;27(120):115-120.
  15. Karasova M, Tothova C, Grelova S, Fialkovicova M. The etiology, incidence, pathogenesis, diagnostics, and treatment of canine babesiosis caused by Babesia gibsoni infection. Animals. 2022;12(6):739-758.
  16. 16. Kettner F, Reyers F, Miller D. Thrombocytopaenia in canine babesiosis and its clinical usefulness. Journal of the South African Veterinary Association. 2003;74(3):63-68.
  17. 17. Lin MY, Huang HP. Use of a doxycyclineenrofloxacin-metronidazole combination with/without diminazene diaceturate to treat naturally occurring canine babesiosis caused by Babesia gibsoni. Acta Veterinaria Scandinavica. 2010;52(27):1-4.
  18. 18. Liu PC, Lin CN, Su BL. Clinical characteristics of naturally Babesia gibsoni infected dogs: A study of 60 dogs. Veterinary Parasitology: Regional Studies and Reports. 2022;28(1):e100675.
  19. Mittal M, Kundu K, Chakravarti S, Mohapatra JK, Singh VK, Kumar BR, et al. Canine babesiosis among working dogs of organised kennels in India: A comprehensive haematological, biochemical, clinicopathological and molecular epidemiological multiregional study. Preventive Veterinary Medicine. 2019;169(1):e104696.
  20. 20. Nayak D, Chadha V, Jain S, Nim P, Sachdeva J, Sachdeva G, et al. Effect of adjuvant homeopathy with usual care in management of thrombocytopenia due to dengue: a comparative cohort study. Homeopathy and Public Health. 2019;32(03):150-157.
  21. 21. Reddy STC, Chandrashekhariah AKM, Appaiah KM, Murag S, Kumar KRA, Hanumantha PB. Haemato-Biochemical Changes in Dogs Affected with Immune Mediated Haemolytic Anaemia Caused by Babesia gibsoni. Indian Journal of Veterinary Sciences & Biotechnology. 2024;20(4).
  22. 22. Salem NY, Farag HS. Clinical, hematologic, and molecular findings in naturally occurring Babesia canis vogeli in Egyptian dogs. Veterinary Medicine International. 2014;1:1-6.
  23. 23. Selvaraj P, Senthil Kumar K, Vairamuthu S, Prathaban S, Srinivasan SR. Babesia gibsoni -An emerging challenge in canine pediatric practice in Chennai. Tamil Nadu Journal of Veterinary and Animal Sciences. 2010;6(3):122-124.
  24. 24. Shah SA, Sood NK, Tumati SR. Haematobiochemical changes in natural cases of canine babesiosis. Asian Journal of Animal Sciences. 2011;5(6):387-392.
  25. Shrivastava S, Shukla PC, Roy K. Evaluation of drugs combinations against canine babesiosis. BIOINFOLETA Quarterly Journal of Life Sciences. 2014;11(2b):491496.
  26. 26. Solano-Gallego L, Baneth G. Babesiosis in dogs and cats-expanding parasitological and clinical spectra. Veterinary Parasitology. 2011;181(1):48-60.
  27. 27. Taboada J, Merchant SR. Babesiosis of companion animals and man. Veterinary Clinics of North America: Small Animal Practice. 1991;21(1):103-123.
  28. 28. Tungnunga I, Sarma K, Roychoudhury P, Borthakur S, Das G, Prasad H, et al. Therapeutic evaluation of homoeopathic drug Crotalus horridus 200C against Ehrlichiosis-infected dogs in Mizoram. Indian Journal of Research in Homoeopathy. 2016;10(1):42-51.
  29. 29. Yogeshpriya S, Sivakumar M, Saravanan M, Venkatesan M, Veeraselvam M, Jayalakshmi K, et al. Clinical, haemato-biochemical and ultrasonographical studies on naturally occurring Babesia gibsoni infection in dogs. Journal of Entomology and Zoology Studies. 2018;6(1):1334-1337.
  30. 30. Zygner W, Gójska O, Rapacka G, Jaros D, Wędrychowicz H. Hematological changes during the course of canine babesiosis caused by large Babesia in domestic dogs in Warsaw (Poland). Veterinary Parasitology. 2007;145(1-2):146-151.
  31. Baneth G, Florin-Christensen M, Cardoso L, Schnittger L. Reclassification of Theileria annae as Babesia vulpes sp. nov. Parasites & vectors. 2015 Apr 8;8(1):207.
  32. Lakshmi VU, Rakesh MP, Narmadha MP, Sudhindran S, Balakrishnan D, Koyakutty M. The clinical utility of circulating tumor DNA in colorectal cancer: A narrative review. Cancer Research, Statistics, and Treatment. 2024 Oct 1;7(4):435-46.
  33. Nagarjuna N, Kavitha S. A Data-Driven Approach in predicting Heart Disease Detection in earlier stage. In2024 2nd International Conference on Networking and Communications (ICNWC) 2024 Apr 2 (pp. 1-8). IEEE.
Vector-borne infectious diseasesComplementary and Alternative Medicine StudiesBrucella: diagnosis, epidemiology, treatmentBabesia gibsonimetronidazolediminazene aceturateenrofloxacinCrotalus horridusthrombocytopeniadogscanine babesiosishemolytic anemiadoxycycline
Citations
0
FWCI
0.00
field-weighted impact
References
0
Percentile
60%
vs. same field & year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.